Law360, New York (January 15, 2015, 4:28 PM EST) -- The U.S. Food and Drug Administration on Thursday downplayed the unusually small amount of punishment it meted out in 2014 for improper promotion of prescription drugs, saying that the time frame is arbitrary and that lots of less-noticed oversight occurred.
The comments came in response to an inquiry from Law360 after the FDA closed out 2014 having issued just 10 disciplinary letters to drugmakers for minimizing product risks, overstating benefits or otherwise making mistakes in advertisements.
That was by far the lowest level in more than a decade, a period during which the FDA’s Office of Prescription Drug Promotion — previously...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!